Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Socially responsible companies are businesses that integrate social and environmental considerations into their core operations and decision-making processes.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

The skyrocketing popularity of weight-loss drugs like Wegovy, one of a class of drugs called GLP-1s, is fast becoming a state ...

The risk of heart attack and stroke declines, but gastrointestinal problems and joint inflammation increase: New research has shed more light on the pros and cons of weight-loss jabs.

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...